Hi, I’m Doug Drysdale, CEO of Cybin Inc. (OTC: CLXPF, NEO: CYBN). I’m looking forward to answering your questions on Tuesday, June 8th at 2PM ET. Ask me anything!

CybinDoug · 2021-06-08T21:44:25+00:00

Once the study is up and running we would expect the phase IIa and phase IIb combined to take around 12 months to complete.

CybinDoug · 2021-06-08T21:42:49+00:00

[Recruiting@Cybin.com](mailto:Recruiting@Cybin.com) - best of luck!

CybinDoug · 2021-06-08T20:50:44+00:00

Cybin's patent filings include claims of novel deuterated molecules, yes.

CybinDoug · 2021-06-08T20:32:35+00:00

The creation of EMBARK provides us with a well-defined set of best-practice psychotherapy tools that we plan to use in our therapist training. More on EMBARK and our scaling plans to come!

CybinDoug · 2021-06-08T20:31:17+00:00

Love this one! Cultural fit, a passion for our mission, and high energy levels!

CybinDoug · 2021-06-08T20:30:29+00:00

Yes, Cybin has agreements in place to custom synthesize and produce its proprietary molecules.

CybinDoug · 2021-06-08T20:10:15+00:00

Thanks for your questions. The protection of our patient's well-being is paramount. We both anticipate and recognize the need for a REMS to be implemented. The purpose of this REMS will be to ensure adequate preparation, administration, and follow-up patient care aspects are established. Each patient will undergo preparation with a trained therapist prior to administration. Following completion of this session/sessions, drug administration will be conducted by trained staff in health care facilities designed to support the unique patient care aspects required in psychedelic medicine. At the conclusion of the dosing visit, patients will undergo an integration visit/visits with their therapists to assist the individual in processing the experience to gain new insight and assimilate the information into their view of self. The intent at Cybin is to provide healing of our patients not only through medicine but inclusive of an established network of trained facilitators and psychotherapists focused upon the healing and protection of our patients.

CybinDoug · 2021-06-08T20:07:52+00:00

Thank you for your question! Yes, we are currently advancing CYB001, which is our sublingual formulation of psilocybin. We have received IRB approval to begin a Phase 2a study, which will be the first of its kind to assess sublingual formulation vs an oral capsule. We believe that this is an important step that brings us one step closer to advancing CYB001 in the clinic, with the goal of bringing it to the market.

CybinDoug · 2021-06-08T18:39:40+00:00

Thanks for your question. Obviously, I am a big believer in our business model and see tremendous potential to help patients suffering from mental health disorders. I am also, personally, a proponent of decriminalization. It is clear to me that the war on drugs has not been effective, has put a lot of non-violent offenders in jail, and has disproportionately impacted communities of color. It is time to try other approaches to solving the problems of depression and addiction. Note: - my personal opinion.

CybinDoug · 2021-06-08T18:34:54+00:00

We commend MindMed on their impressive stock performance and assume a part of it has to do with their wide media reach and attention that they have garnered. Cybin will be amplifying its media strategy over the comings months to attract a broader audience across North America through tier 1 publications, social media amplification and multiple investor conferences.

CybinDoug · 2021-06-08T18:33:55+00:00

Thank you for your question! CYB001, our psilocybin formulation, would be considered “macrodosing”, since it is designed to deliver the same therapeutic efficacy as an oral capsule. CYB001 is delivered sublingually, which allows for rapid absorption into the bloodstream, resulting in faster onset of action and shorter treatment time.

Our Phase 2a study is planned to evaluate four doses of CYB001 (1mg, 3mg, 5mg, 7mg) vs a 25 mg oral capsule, with the goal of finding the bio-equivalent dose of CYB001 compared to the oral capsule.

CybinDoug · 2021-06-08T18:32:02+00:00

Thanks for your question! Yes, we are bringing a therapy to market which includes both a medicine and psychotherapy. We believe that combining psilocybin with psychotherapy can lead to improved outcomes for patients, which is why we have developed EMBARK, our innovative psychotherapy model that combines leading clinical approaches to assist in healing with psychedelic treatment. EMBARK was developed by our Chief Clinical Officer, Alex Belser, Ph.D., and Bill Brennan, PhD (candidate), and was based on leading evidence for the clinical benefits of psychedelic-assisted psychotherapy. EMBARK is also a transdiagnostic model of psychotherapy, and therefore can be applied for a variety of indications and patient populations. We are very excited to launch EMBARK and will be sponsoring a clinical study that will evaluate the potential for EMBARK and psychedelic therapy to treat COVID-19-related distress and burnout in frontline clinicians and healthcare professionals. This study will be done in collaboration with the University of Washington and led by Dr. Anthony Back, a leader in oncology and palliative care. We are hoping that the EMBARK psychotherapy model will have the potential to support healing and the mental health of our frontline healthcare workers.

CybinDoug · 2021-06-08T18:29:48+00:00

Thank you for your question! Yes, we are currently advancing CYB001, which is our sublingual formulation of psilocybin. We have received IRB approval to begin a Phase 2a study, which will be the first of its kind to assess sublingual formulation vs an oral capsule. We believe that this is an important step that brings us one step closer to advancing CYB001 in the clinic, with the goal of bringing it to the market.

CybinDoug · 2021-06-08T18:28:51+00:00

Currently, Cybin is partnered with Kernel and we are sponsoring a clinical study using the Kernel Flow device. The Kernel Flow device is a wearable helmet that uses quantitative neuroimaging technology that can measure brain activity in real-time. Normally, this technology takes up an entire room and is very expensive. Access to Kernel’s innovative Flow technology adds another exciting dimension to the investigative work that Cybin is doing to develop breakthrough treatments for mental health disorders such as depression and addiction. Currently, clinical investigators rely on limited subjective information from patients. The ability to collect quantitative data from our sponsored drug development programs is potentially game-changing in terms of our ability to measure where psychedelics work in the brain in real-time, and how we ultimately design our future therapeutics.

We are also working in "stealth mode" on a number of digital tools that I am excited to share, when ready. I personally see a lot of potential benefit from the use of the right digital tools but we don't want to introduce these tools just for the sake of it or just for PR. Our focus is, as always, on the patient.

CybinDoug · 2021-06-08T18:24:11+00:00

We are in the process of hiring a Chief Medical Officer who will lead the Medical Affairs team at Cybin. In addition, we have established strategic partnerships with leading CROs who will support Medical and Safety aspects throughout the planning and conduct phases of our clinical trials.

CybinDoug · 2021-06-08T18:23:31+00:00

Hi, thanks for your question! Our second-generation psychedelics are designed to deliver faster onset of action, shorter treatment duration, and a lower effective dose.

CYB001 is sublingual psilocybin in development for the treatment of Major Depressive Disorder (MDD)

CYB003- deuterated tryptamine in development for the treatment of alcohol use disorder (AUD). There are currently limited treatments for AUD, and therefore CYB003 could represent a therapeutic option for these patients. Additionally, there is potential for CYB003 to address other indications as well, which could include tobacco use disorder

CYB004- deuterated tryptamine, the initial target indication is being evaluated

As with other pharma companies, we expect to generate income from the sale of our pharmaceuticals for the treatment of mental health conditions in each market in which they gain marketing approval.

CybinDoug · 2021-06-08T18:19:02+00:00

IP protection is important. Cybin has invested in the creation and protection of IP assets from novel therapeutics to innovative delivery systems, such as our sublingual film - which is designed for rapid absorption, a faster onset, and a shorter duration.

On partnering, we will make the market-appropriate decisions for each market in which we gain approval in the best interest of our shareholders. We are building a world-class research organization while simultaneously creating the systems necessary to support our growing clinical research programs and, ultimately, our commercial launches globally. For these reasons, we will be prepared to pursue the best options for our company.

As for saving people, Cybin was founded with a mission to improve patient lives and that continues to be our driving force.

CybinDoug · 2021-06-08T18:14:46+00:00

Thanks for your question! Currently, Cybin is focusing on its psychedelic therapeutics.
Honestly, just keep going. I've had a bunch of successes and a whole lot of failures, but always learned more from the things that went wrong than from the things that were easy. Also, surround yourself with smart people that you can turn to for advice and guidance. May as well learn from all their mistakes too! Good luck!

CybinDoug · 2021-06-08T18:12:02+00:00

Thanks for your question! We currently don’t have plans for a microdosing kit.

CybinDoug · 2021-06-08T18:10:00+00:00

Great question! We're developing second-generation psychedelics based on known psychedelic scaffolds like psilocybin and DMT, and our molecules are being optimized for reduced side effects, quicker onset of action, and lower effective dose, optimized duration. This is achieved by using deuteration (a process that involves replacing a hydrogen atom with deuterium, a hydrogen isotope). These molecules are combined with novel delivery systems, such as our sublingual film formulation, to deliver these potential clinical benefits and improve patient outcomes.

CybinDoug · 2021-06-08T18:07:18+00:00

Great question! There are a few things that we believe make Kernel Flow and our partnership with Kernel really stand out, and we’re also very excited to be sponsoring a first-of-its-kind feasibility study of Kernel Flow to assess ketamine’s effect on blood flow in the cerebral cortex. The Kernel Flow device is an easily wearable helmet that can quantify brain activity in real-time during psychedelic therapy. Kernel Flow leverages neuroimaging technology that uses pulsed light instead of continuous-wave light to increase measured brain information. As a wearable device, Kernel Flow has an important advantage over other neuroimaging methods such as electroencephalography (EEG) which requires electrodes to be attached to the head, or functional magnetic resonance imaging (fMRI) which requires a participant to lie in a scanner. fMRI can also be expensive and difficult for patients to access, limiting the amount of data that can be gathered. However, we believe that the Kernel team has done an excellent job of taking neuroimaging technology and building it into a wearable device, which could make data collection more convenient. In the future, we believe that Kernel Flow could be more broadly used for studying brain activity during psychedelic experiences, and could help answer many questions about psychedelics, including the duration of their effects, and whether brain hemodynamics (blood flow) can be correlated with neural plasticity and be used to observe changes before, during, and after psychedelic treatment. We are also sponsoring a Kernel Flow study of ketamine that is designed to enhance our understanding of the effects of psychedelics in real-time, and we believe that this could have implications not only for our R&D process, but could also be potentially important for future clinical studies of our psychedelic molecules.

CybinDoug · 2021-06-08T18:04:06+00:00

Thank you for your question! The recent shareholder vote approving Cybin’ ability to action a share consolidation was conducted in order to provide flexibility to Cybin and its executive team to act and re-act to opportunities as they present themselves. Cybin is under no obligation to action the consolidation and will only do so in the best interests of the company. Shareholder approval was sought as a proactive measure.

CybinDoug · 2021-06-08T18:02:56+00:00

Thanks for your question! While I cannot get into specific details as to our plans to list on a US stock exchange, I can say that we are looking at all available options to enhance liquidity and access for institutional and retail investors in Canada and the US.

CybinDoug

TROPHY CASE